FDA approves female sexual dysfunction drug

  title={FDA approves female sexual dysfunction drug},
  author={Asher Mullard},
  journal={Nature Reviews Drug Discovery},
  • Asher Mullard
  • Published 1 October 2015
  • Medicine
  • Nature Reviews Drug Discovery
resubmitted the drug in 2013, with data from a third pivotal trial, only to have it rejected again that year. Sprout resubmitted the drug this year with additional safety data. At an FDA advisory meeting in June, independent experts voted 18 to 6 to approve the drug with a risk evaluation and mitigation strategy (REMS). This vote and the approval a few months later led some critics to note that marketing tactics — including an effort by ‘Even The Score’, a Sprout-funded advocacy group, to… 
2 Citations

Patient speaking for patients

The history of flibanserin, a controversial new drug to treat a debatable condition, illustrates how a public relations campaign could circumvent the well-established process to weigh evidence of potential harm vs benefit by one of the most robust drug regulators in the world.

Synthetic Approaches to the New Drugs Approved During 2015.

This annual review describes the most likely process-scale synthetic approaches to 29 new chemical entities (NCEs) that were approved for the first time in 2015.